Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 USD | -0.37% | +19.55% | -11.19% |
Financials (USD)
Sales 2024 * | 401M | Sales 2025 * | 486M | Capitalization | 1.1B |
---|---|---|---|---|---|
Net income 2024 * | -128M | Net income 2025 * | -74M | EV / Sales 2024 * | 3.32 x |
Net Debt 2024 * | 234M | Net Debt 2025 * | 259M | EV / Sales 2025 * | 2.79 x |
P/E ratio 2024 * |
-8.73
x | P/E ratio 2025 * |
-13.3
x | Employees | 536 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.09% |
Latest transcript on BioCryst Pharmaceuticals, Inc.
1 day | -0.37% | ||
1 week | +19.55% | ||
Current month | +28.81% | ||
1 month | +11.53% | ||
3 months | -10.59% | ||
6 months | +6.83% | ||
Current year | -11.19% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 0 M€ | 0.00% | - | |
0.20% | 0 M€ | 0.00% | - | |
0.18% | 0 M€ | +7.73% | - | |
0.13% | 0 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 5.32 | -0.37% | 3,502,122 |
24-05-09 | 5.34 | +4.71% | 3,357,148 |
24-05-08 | 5.1 | -3.04% | 3,789,588 |
24-05-07 | 5.26 | -0.19% | 6,215,852 |
24-05-06 | 5.27 | +18.43% | 8,898,733 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.19% | 1.1B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BCRX Stock